TABLE 3

In vitro scaled and fitted sandwich culture human hepatocyte estimates

Compound	SCL_{int, u, act}			SCL_{int, u, pass}			SCL_{int, u, bile}
Compound	In Vitro-Scaled	In Vivo-Fitted	Scaling Factor	In Vitro-Scaled	In Vivo-Fitted	Scaling Factor	In Vitro-Scaled	In Vivo-Fitted	Scaling Factor
	l/h
Pravastatin	19	406	21	1.1	4.2	3.9	12	1.5	0.12
Cerivastatin	102	12,827	126	265	153	0.58	182^{^a}	55^{^a}
Bosentan	96	8489	89	51	59	1.2	165^{^a}	21^{^a}
Fluvastatin	475	76,513	161	208	147	0.71	485^{^a}	86^{^a}
Rosuvastatin	98	1190	12	18	1.7	0.10	16	1.2	0.079
Valsartan	22	2463	110	6.4	23	3.7	1017	25	0.024
Repaglinide	319	13,941	44	938	1477	1.6	0	0
Geometric mean			58			1.0			0.061

↵a Repesents the sum of SCL_{int, u, bile} and SCL_{int, u, met} because for these three compounds both CL mechanisms are occurring and they cannot be uniquely identified in the fitting process.